Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J SCHAAF

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Pharmacology|August 30, 2011
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumorsElaine T Lam, Sanjay Goel, Larry J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerR F DeVore, D H Johnson, J Crawford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patientsJ Paul Monk, Gary Phillips, Ross Waite, et al.
Therapeutic Drug Monitoring|August 19, 2008
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasmaQing Liu, Katherine L Farley, Amy J Johnson, et al.
Acta Neuropathologica Communications|October 30, 2015
Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe diseaseGerben J Schaaf, Tom J M van Gestel, Esther Brusse, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Journal of the National Cancer Institute|February 6, 2016
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination RepairMiguel A Villalona-Calero, Wenrui Duan, Weiqiang Zhao, et al.
Acta Neuropathologica Communications|November 9, 2018
Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe diseaseGerben J Schaaf, Tom J M van Gestel, Stijn L M In 't Groen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancyEdward J Licitra, Viral Vyas, Kathy Nelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyH C Pitot, R M Goldberg, J M Reid, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|August 30, 2011
Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumorsElaine T Lam, Sanjay Goel, Larry J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancerR F DeVore, D H Johnson, J Crawford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patientsJ Paul Monk, Gary Phillips, Ross Waite, et al.
Therapeutic Drug Monitoring|August 19, 2008
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasmaQing Liu, Katherine L Farley, Amy J Johnson, et al.
Acta Neuropathologica Communications|October 30, 2015
Lack of robust satellite cell activation and muscle regeneration during the progression of Pompe diseaseGerben J Schaaf, Tom J M van Gestel, Esther Brusse, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Journal of the National Cancer Institute|February 6, 2016
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination RepairMiguel A Villalona-Calero, Wenrui Duan, Weiqiang Zhao, et al.
Acta Neuropathologica Communications|November 9, 2018
Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe diseaseGerben J Schaaf, Tom J M van Gestel, Stijn L M In 't Groen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancyEdward J Licitra, Viral Vyas, Kathy Nelson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyH C Pitot, R M Goldberg, J M Reid, et al.
Pageof 10